Ingrezza
(Valbenazine)ApprovedSmall molecule
Neurocrine BiosciencesValbenazine is used to treat involuntary repetitive movements and tics, particularly tardive dyskinesia, which is a condition that can develop as a side effect of certain psychiatric medications.[2] Ingrezza is currently approved and in use across 12 indications[4].[1]
Ingrezza is one of 201 small molecule programs targeting Cervical Dystonia. It is currently in Approved.
12
Indications
20
Total Trials
7
Active Trials
200
Competitors
2
FDA Applications
NDA/BLA/ANDA regulatory filings
22
Patents
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 12 indications
Competition
Competitive Landscape
583 competitors in Schizophrenia
#DrugCompanyPhaseTrials
1Ingrezza
Neurocrine BiosciencesApproved
Celexa
AbbViePreclinical
Ozempic
Novo NordiskPreclinical
Resotran
TakedaPreclinical
Inapsine
Alnylam PharmaceuticalsPreclinical
Zocor
OOrganon and Co
Preclinical
Depakote
AbbViePreclinical
Ibrance
PfizerPreclinical
Lunesta
Akero TherapeuticsPreclinical
Luvox
SSolvay Pharmaceuticals
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Tardive Dyskinesia6 trials
Tourette syndrome4 trials
Huntington disease3 trials
Schizophrenia2 trials
4 more indications
Withdrawal1 trial
Cerebral Palsy1 trial
Regulatory
FDA Approval Timeline[5]
Apr 11, 2017
INGREZZA
NDA NDA209241
Apr 30, 2024
INGREZZA SPRINKLE
NDA NDA218390
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Ingrezza drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Valbenazine. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]
Details
Drug Info
Quick Facts
- Mechanism of Action
- VMAT2 Inhibitor[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
Patent Landscape[6]
Patent Cliff
Nov 8, 2027
Earliest patent expiration — generic entry possible after this date
Patent #Expires
8357697Nov 8, 2027
8039627Apr 11, 2031
10844058Oct 28, 2036
10065952Oct 28, 2036
10851104Oct 28, 2036
17 more patents
10851103Oct 28, 2036
10919892Dec 22, 2036
10906902Dec 22, 2036
10906903Dec 22, 2036
10857137Oct 10, 2037
11040029Oct 10, 2037
10993941Oct 10, 2037
10874648Oct 10, 2037
10857148Oct 10, 2037
10952997Oct 10, 2037
11439629Oct 10, 2037
10912771Oct 10, 2037
11311532Sep 18, 2038
11026939Sep 18, 2038
11654142Nov 14, 2038
11026931Aug 14, 2039
10940141Aug 10, 2040